Back A A A Font Size Receive E-mail Alerts Press Releases

Mr. Noboru Shimizu Joined MicroPort® CRM as Vice-President, Country Manager Japan, and Head of Commercial Operations of MicroPort® CRM Japan Co. Ltd.

[2018-12-21] 

Clamart, France – November 26th, 2018 - MicroPort® CRM (a business unit of MicroPort Scientific Corporation), is pleased to announce that Mr. Noboru Shimizu has joined us to take on the role of Vice-President, Country Manager Japan, and head of commercial operations of MicroPort® CRM Japan Co. Ltd., a subsidiary created in August 2018, Tokyo, Japan.
 
Mr. Shimizu has an outstanding track record in working for large multi-national companies such as McKinsey, Guidant, Boston Scientific and most recently IQVIA (Quintiles). Mr. Shimizu brings a wealth of experience and expertise to MicroPort® CRM.
 
Mr. Shimizu graduated from the University of Tokyo with a Bachelor of Science, and the Wharton School at the University of Pennsylvania with an MBA.
 
"The Japanese market is of primary importance to our CRM business. Shimizu-San's long-term strategic vision is fully aligned with that of MicroPort® CRM and I believe that this vision, together with his deep knowledge of the Japanese healthcare market and strong business acumen, will ensure MicroPort® CRM Japan's development and success in the near future" said Benoît Clinchamps, President of MicroPort® CRM.
 
"I'm convinced that Shimizu-Sans's previous CRM experience along with his excellent managerial skills and sound knowledge of the local environment will help guide our organization as we work to widen our reach among Japanese physicians and patients providing greater access to the very best technologies that MicroPort® CRM has to offer," said Philippe Wanstok, Senior Vice President, Global Sales, MicroPort® CRM.

 

About MicroPort® CRM
 
Pioneering physiological therapies in cardiac rhythm management. Driven by our expert R&D teams and state-of-the-art manufacturing facilities across the globe, MicroPort® CRM conceives, designs and develops solutions for the management of cardiac rhythm disorders and heart failure. Headquartered in Paris, our precise technologies are manufactured in France, Italy, the Dominican Republic; and for the Chinese market, in China. MicroPort® CRM is part of MicroPort Scientific Corporation.
 
For more information visit www.crm.microport.com

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 8 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to bringing about a people-centric SuperCluster of emerging medical technologies to provide the best yet accessible ways & means to prolong and reshape lives.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 1998-2019 MicroPort Scientific Corporation

CONTACT:
Leanne Li
Board Secretary and Vice President of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6957
Email: spokesperson@microport.com

 

[Prev]:MicroPort® CRM Announces European Launch of World's Smallest 1.5T & 3T MRI Conditional Pacemaker Portfolio*
[Next]:Beflex Active Pacing Lead Family Approved in China